![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
No Significant Effect of the HCV Protease Inhibitor Telaprevir on Pharmacokinetics and Pharmacodynamics of Buprenorphine in HCV-negative Volunteers
|
|
|
Reported by Jules Levin
HEP DART 2011, Koloa, Hawaii, USA, December 4-8, 2011
X Luo1, J Trevejo1, R van Heeswijk2, V Garg*1
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States; 2Tibotec BVBA, Beerse, Belgium
![HepDart1.gif](../images/120611/120611-4/HepDart1.gif)
![HepDart2.gif](../images/120611/120611-4/HepDart2.gif)
![HepDart3.gif](../images/120611/120611-4/HepDart3.gif)
![HepDart4.gif](../images/120611/120611-4/HepDart4.gif)
![HepDart5.gif](../images/120611/120611-4/HepDart5.gif)
![HepDart6.gif](../images/120611/120611-4/HepDart6.gif)
![HepDart7.gif](../images/120611/120611-4/HepDart7.gif)
![HepDart8.gif](../images/120611/120611-4/HepDart8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|